摘要
目的讨论正确面对和处理药品专利常青问题,提出促进我国制药行业创新发展的应对策略。方法分析印度2005年专利法第三条(d)款对已知物质衍生物的药品专利常青禁止性规定的内容、立法背景、争论、意义,并比较美国、欧盟和其他新兴经济体对药品专利常青的规制措施与态度。结果与结论印度专利法第三条(d)款对制药行业增量创新产生负面影响;我国应谨慎对待药品专利常青问题,并考虑在专利审查中提高药品创造性标准。
Objective To find more proper measures to cope with the evergreening of patent in advance and to promote the development of China＇s pharmaceutical industry.Methods This paper analyzes the content,legislative intention,influence and debates on article 3（d）of Indian Patent Law of 2005 and compares different measures and attitudes towards evergreening of pharmaceutical patent in the United States,EU and some emerging economies.Results and Conclusion The stipulation of article 3（d）in Indian Patent Law will be detrimental to the incremental innovation in pharmaceutical industry and China should be cautious to deal with the issue of evergreening of pharmaceutical patent and the pharmaceutical inventiveness standerd should be correspondingly elevated in patent examination.
出处
《中国药事》
CAS
2014年第12期1285-1289,共5页
Chinese Pharmaceutical Affairs
基金
国家社会科学基金重大招标项目"促进自主创新能力建设的国家知识产权政策体系研究"(编号12&ZD073)
国家知识产权局专利保护重点联系机制工作项目(编号20121029952)
关键词
专利常青
印度专利法
第三条(d)款
制药行业
增量创新
药品专利审查
专利标准
evergreening of patent
Indian Patent Law
Article 3（d）
pharmaceutical industry
incremental innovation
drug patents censorship
proprietary standards
